دورية أكاديمية
Health economic evaluation of lung cancer screening using a 2 diagnostic blood test : the Early detection of Cancer of the Lung 3 Scotland (ECLS)
| العنوان: | Health economic evaluation of lung cancer screening using a 2 diagnostic blood test : the Early detection of Cancer of the Lung 3 Scotland (ECLS) |
|---|---|
| المؤلفون: | Robles-Zurita, Jose Antonio, McMeekin, Nicola, Sullivan, Francis, Mair, Frances S, Briggs, Andrew |
| المساهمون: | University of St Andrews. Sir James Mackenzie Institute for Early Diagnosis, University of St Andrews. Population and Behavioural Science Division, University of St Andrews. School of Medicine |
| سنة النشر: | 2024 |
| المجموعة: | University of St Andrews: Digital Research Repository |
| مصطلحات موضوعية: | Cost-effectiveness, Economic valuation, Lung cancer, Screening, Diagnostic blood test, RC0254 Neoplasms. Tumors. Oncology (including Cancer), 3rd-NDAS, SDG 3 - Good Health and Well-being, RC0254 |
| الوصف: | Funding: Funding for the ECLS study was received from Oncimmune Ltd and the Scottish Government Health & Social Care Directorate of the Chief Scientist Office (CSO). ; Background: Diagnostic blood tests have the potential to identify lung cancer in people at high risk. We assessed the cost-effectiveness of a lung cancer screening intervention, using the EarlyCDT®-Lung Test (ECLS) with subsequent X-ray and low-dose chest CT scans (LDCT) for patients with a positive test result, compared to both usual care and LDCT screening for the target population. Methods: We conducted a model-based lifetime analysis from a UK NHS and personal social services perspective. We estimated incremental net monetary benefit (NMB) for the ECLS intervention compared to no screening and to LDCT screening. Results: The incremental NMB of ECLS intervention compared to no screening was GBP 33,179 (95% CI: −GBP 81,396, GBP 147,180) and GBP 140,609 (95% CI: -GBP 36,255, GBP 316,612), respectively, for a cost-effectiveness threshold of GBP 20,000 and GBP 30,000 per quality-adjusted life year. The same figures compared with LDCT screening were GBP 162,095 (95% CI: GBP 52,698, GBP 271,735) and GBP 52,185 (95% CI: −GBP 113,152, GBP 220,711). Conclusions: The ECLS intervention is the most cost-effective screening alternative, with the highest probability of being cost-effective, when compared to no screening or LDCT screening. This result may change with modifications of the parameters, suggesting that the three alternatives considered in the main analysis are potentially cost-effective. ; Peer reviewed |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | application/pdf |
| اللغة: | English |
| تدمد: | 1718-7729 |
| العلاقة: | Current Oncology; 303436152; a7855fd9-f8a4-41ef-a68b-08b068df7cdc; Robles-Zurita , J A , McMeekin , N , Sullivan , F , Mair , F S & Briggs , A 2024 , ' Health economic evaluation of lung cancer screening using a 2 diagnostic blood test : the Early detection of Cancer of the Lung 3 Scotland (ECLS) ' , Current Oncology , vol. 31 , no. 6 , pp. 3546-3562 . https://doi.org/10.3390/curroncol31060261Test; ORCID: /0000-0002-6623-4964/work/162168516; https://hdl.handle.net/10023/30038Test; https://www.mdpi.com/1718-7729/31/6/261Test |
| DOI: | 10.3390/curroncol31060261 |
| الإتاحة: | https://doi.org/10.3390/curroncol31060261Test https://hdl.handle.net/10023/30038Test https://www.mdpi.com/1718-7729/31/6/261Test |
| رقم الانضمام: | edsbas.EB747E0 |
| قاعدة البيانات: | BASE |
Full Text Finder | تدمد: | 17187729 |
|---|---|
| DOI: | 10.3390/curroncol31060261 |